Verrica Pharmaceuticals Inc. Overview
Pro stress-test →Verrica Pharmaceuticals is a dermatology therapeutics company engaged in the development and sale of medications for the treatment of skin diseases in the United States. YCANTH (VP-102) is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States. The company is capitalizing on significant unmet medical needs with an expanding pipeline and recent international expansion.
Strategic Profile
Pro stress-test →YCANTH is in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. The company is positioned as a focused dermatology player with blockbuster potential across multiple viral skin conditions and oncologic indications.
Competitive Landscape
Pro stress-test →Verrica operates in the dermatology therapeutics space with minimal direct competition for YCANTH in molluscum contagiosum. The common warts market is a multibillion-dollar opportunity with no FDA-approved prescription therapies, positioning Verrica as a potential pioneer. In oncologic dermatology with VP-315, the company competes in a broader field of skin cancer treatments.
Industry Context
Verrica Pharmaceuticals Inc. operates in Dermatology Therapeutics / Specialty Pharmaceuticals.
Key facts
Headquarters: West Chester, Pennsylvania, United States · Revenue: $14.3M (Q3 2025)